Cargando…

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update

The management of advanced nonsmall cell lung cancer (NSCLC) patients is becoming increasingly complex with the identification of driver mutations/rearrangements and development/availability of appropriate targeted therapies. In 2017, an expert group of medical oncologists with expertise in treating...

Descripción completa

Detalles Bibliográficos
Autor principal:	Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348782/ https://www.ncbi.nlm.nih.gov/pubmed/30766843 http://dx.doi.org/10.4103/sajc.sajc_227_18

Ejemplares similares

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
por: Li, Ying, et al.
Publicado: (2014)

Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
por: Bluthgen, Maria-Virginia, et al.
Publicado: (2015)

Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
por: Pandey, Avinash Vijaykumar, et al.
Publicado: (2015)

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer
por: Yu, Jing, et al.
Publicado: (2015)

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
por: Tinker, Anna V., et al.
Publicado: (2022)

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
por: Sebastian, Martin, et al.
Publicado: (2014)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Zhang, Jie, et al.
Publicado: (2021)

Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis
por: Cao, Rui, et al.
Publicado: (2019)

Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy
por: Rajappa, Senthil, et al.
Publicado: (2017)

The Possibility of Traditional Chinese Medicine as Maintenance Therapy for Advanced Nonsmall Cell Lung Cancer
por: Xu, Weiru, et al.
Publicado: (2014)

Update on first-line treatment of advanced ovarian carcinoma
por: Kemp, Z, et al.
Publicado: (2013)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

The second ESGAR consensus statement on CT colonography
por: Neri, Emanuele, et al.
Publicado: (2012)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Updated ACVIM consensus statement on leptospirosis in dogs
por: Sykes, Jane E., et al.
Publicado: (2023)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Consensus statement on the management of dyslipidemia in Indian subjects: Our perspective
por: Bansal, Manish, et al.
Publicado: (2016)

Updated diagnosis, treatment and prevention of COVID-19 in children: experts’ consensus statement (condensed version of the second edition)
por: Shen, Kun-Ling, et al.
Publicado: (2020)

A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?
por: Lin, Jia-Zhou, et al.
Publicado: (2018)

Interleukin-33 Involvement in Nonsmall Cell Lung Carcinomas: An Update
por: Casciaro, Marco, et al.
Publicado: (2019)

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update
por: Godse, Kiran, et al.
Publicado: (2018)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

An update of the consensus statement on insulin resistance in children 2010
por: Tagi, Veronica Maria, et al.
Publicado: (2022)

A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum
Publicado: (2019)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
por: Walleser, Silke, et al.
Publicado: (2012)

Association of First-Line and Second-Line Antiretroviral Therapy Adherence
por: Ramadhani, Habib O., et al.
Publicado: (2014)

Nutritional treatment of advanced CKD: twenty consensus statements
por: Cupisti, Adamasco, et al.
Publicado: (2018)

First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view
por: Thatcher, Nicholas
Publicado: (2008)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
por: Chouaïd, Christos, et al.
Publicado: (2014)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Sport and exercise genomics: the FIMS 2019 consensus statement update
por: Tanisawa, Kumpei, et al.
Publicado: (2020)

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011)

Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines
por: Das, Taraprasad, et al.
Publicado: (2016)

It is time for consensus on ‘consensus statements’
por: Blazey, Paul, et al.
Publicado: (2022)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uah1q7am0nsg3q3tfbne845msk